Ascendiant Capital Markets Lowers Aclarion (NASDAQ:ACON) Price Target to $1.30

Aclarion (NASDAQ:ACON) had its price target trimmed by Ascendiant Capital Markets from $1.50 to $1.30 in a report released on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Aclarion Price Performance

NASDAQ ACON opened at $0.18 on Wednesday. Aclarion has a one year low of $0.16 and a one year high of $7.40. The company’s 50-day simple moving average is $0.18 and its two-hundred day simple moving average is $0.24.

Hedge Funds Weigh In On Aclarion

An institutional investor recently bought a new position in Aclarion stock. Virtu Financial LLC purchased a new stake in Aclarion, Inc. (NASDAQ:ACON) during the first quarter, according to its most recent filing with the SEC. The firm purchased 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned 1.40% of Aclarion at the end of the most recent quarter. 7.52% of the stock is owned by institutional investors.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.